Novo has backed automated molecule and material discovery business Kebotix, co-founded by former Harvard University professor Alán Aspuru-Guzik.
Kebotix, a US-based automated chemicals development spinout of Harvard University, secured $11.4m yesterday as part of a series A round led by pharmaceutical firm Novo.
The company did not reveal a target size but noted that the round would remain open to additional investors for a month.
Founded in 2017, Kebotix is developing new molecules and materials using an artificial intelligence-powered lab, expediting medical and industrial projects for both private and public sector clients.
During work for…
